Some deputies to the National People's Congress and deputies to the People's Congress of Guangdong Province and Guangzhou City who are in Guangzhou for the upcoming Two Sessions of the National People's Congress will conduct a centralized inspection
Find out how Guangzhou can stay in the “first echelon” of biomedicine
Dreaming about modernization and drawing a new picture together
The first adalimumab biosimilar approved for marketing in China, China’s first and currently only BTK inhibitor approved for the indication of relapsed and refractory marginal zone lymphoma, 100% independent new drug development capabilities... Guangzhou Biomedicine The industry rally call is sounding!
Recently, the Standing Committee of the Guangzhou Municipal People's Congress organized some deputies to the National People's Congress and deputies to the Guangdong Province and Guangzhou Municipal People's Congress in Guangzhou to carry out centralized inspection activities.
Visiting important science and innovation carriers such as Huangpu District Science City, Knowledge City, and Bio-Island, and going deep into enterprises, hospitals, and R&D institutions, the National People's Congress representatives investigated the development status of Guangzhou's biopharmaceutical industry around "adhering to the real economy as the basis and manufacturing as the leader". Understand the difficulties and obstacles in the transformation of scientific and technological innovation achievements.
Whether it is scientific research and innovation capabilities, project construction speed, or the significantly improved localization rate, the representatives can feel the vitality of Guangzhou's biopharmaceutical industry.
Through this small incision research activity, the NPC deputies expressed that they will continue to pay attention to and support the development of Guangzhou's biopharmaceutical industry in future work, and contribute to promoting the high-quality development of Guangzhou's economy.
Let more “Made in China” biomedical products serve Chinese patients
Guangzhou Science City is a high-end biomedical industry cluster, attracting many well-known domestic and foreign companies and scientific research teams.
“In the past, in domestic treatment, the average annual cost of biological drug treatment for a single rheumatism patient and psoriasis patient was nearly 200,000 yuan. After the launch of Gloria, the average annual cost of drug treatment for a single patient has dropped to 20,000 yuan now. It is diversified and costs less than 8,000 yuan after medical insurance reimbursement, which reduces treatment costs by 90%." Lin Jian, deputy general manager of Biotech Biopharmaceutical Co., Ltd., said that the company is constantly achieving technological innovation, accelerating the transformation of scientific research results, and allowing more people to Chinese biopharmaceuticals developed in China and produced in China are going global.
The launch of new drugs can effectively alleviate the financial burden on patients, and interventional therapy, as a minimally invasive treatment method, can solve disease problems and allow patients to reduce trauma and recover quickly.
Guangzhou Yijie Medical Technology Co., Ltd. was established in 2020. Although it is young, in the three years since its establishment, the company has successively had ten products approved by NMPA and two products approved by FDA.
Yijie provides interventional treatment to solve difficult and complicated diseases such as cerebral obstruction and stroke.
"In the past, most interventional treatments for diseases such as stroke relied on imported products. We hope to achieve import substitution by developing more cutting-edge products so that more domestically produced products can serve Chinese patients," said Xiong Xiaoying, general manager of Yijie Medical.
"The biomedical industry is closely related to people's health. Innovation in biomedicine may largely solve the people's problems with cataracts, cancer and other diseases." Representative to the National People's Congress, Deputy Manager of the Safety and Environmental Protection Department and Youth League Committee of Guangzhou Port Huangpu Port Branch Deputy Secretary Zhou Chong lamented.
Accelerate the construction of a world-class biopharmaceutical industry cluster
Driving along Kowloon Avenue, brand-new buildings and parks stand on both sides.
The constantly renewed Sino-Singapore Guangzhou Knowledge City is also surging with the momentum of biomedicine.
The representatives walked into the Biomedical Value Innovation Park of Sino-Singapore Guangzhou Knowledge City. Here, Guangzhou Nuocheng Jianhua Pharmaceutical Technology Co., Ltd., co-founded by Dr. Cui Jisong and Academician Shi Yigong, is stepping up its research in the field of malignant tumors and autoimmune diseases. Development of a new class of drugs.
Kangfang Biologics, which is not far from InnoCare, is one of the very few companies in the country that has a complete and complete full-chain independent new drug development system, production system and commercialization system.
At present, Kangfang Biologics has developed more than 30 innovative drug candidates with completely independent intellectual property rights, including 6 bispecific antibody drugs, and has become one of the innovative antibody drug R&D companies with the richest pipeline in my country.
The relevant person in charge of Guangdong Ruiheng Pharmaceutical Co., Ltd. used the "Four Highs" to summarize the secrets for enterprises to achieve innovation and international transformation:
High-intensity investment, the company has invested a total of 29.2 billion yuan in R&D in the past ten years; high-level talent recruitment has created a global R&D team of more than 5,000 people; high-level innovation has established proteolysis-targeted chimeras, molecular glues, and antibody conjugates. A number of world-class new technology platforms with independent intellectual property rights, such as United Drugs, are transformed with high efficiency. At present, the company has 13 self-developed innovative drugs, 2 imported innovative drugs approved for marketing, and more than 80 independently innovative products. It is under clinical development and more than 270 clinical trials have been carried out at home and abroad.
Create the “first echelon” of the biopharmaceutical industry
Surrounded by water and adjacent to the University Town, as the core of Guangzhou's "one core and two poles" high-end biomedical industry spatial layout, Guangzhou International Bio-Island has gathered more than 500 biomedical companies. Its industrial competitiveness continues to consolidate and improve, accelerating the construction of global biomedical innovation. and industrial development highlands.
Taking the lead in Guangzhou's "chain length system" implantable and high-performance medical device sub-chain, and establishing an industry incubation fund with an initial scale of 170 million yuan... The Guangdong-Hong Kong-Macao Greater Bay Area High-Performance Medical Device Innovation Center located in the Bio-Island is currently Efforts will be made to gather innovative resources such as domestic and foreign talents and technologies, accelerate the breakthrough of industrial "stuck neck" problems, and accelerate the industrialization of cutting-edge scientific and technological achievements at home and abroad.
Representatives of the National People’s Congress walked into the innovation center to see how high-performance medical devices can make medical solutions more professional, disease detection more accurate, and patients’ recovery faster.
According to reports, in 2023, the total output value of Guangzhou's biomedicine and health care industry will reach 117.8 billion yuan, which is one of the strategic emerging industries focused on development by Guangzhou.
Guangzhou's biopharmaceutical industry is the only strategic emerging industry cluster in Guangdong Province that has received incentives and commendations from the State Council for three consecutive years. In 2023, it was rated as excellent in the national cluster evaluation, and its development level ranks among the first echelons in the country.
"It is precisely because of the proactive actions of successive governments that Guangzhou's biopharmaceutical industry can achieve what it is today." In the eyes of Yuan Yuyu, a representative of the National People's Congress and chairman of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., Guangzhou has a profound biopharmaceutical foundation. There are many tertiary hospitals, scientific research institutes and universities, and a gathering of outstanding medical professionals. It is even more necessary to further transform development potential into a driving force for industrial innovation.
Yuan Yuyu revealed that the purpose of his participation in this survey was to find out the institutional obstacles faced by Guangzhou's biopharmaceutical industry in the process of further development and growth.
"The research and development cycle of the biomedical industry is long, the investment is large, and there are relatively high risks. How can national policies and the market better support industry development? I think there are four chains in the biomedical field: industrial chain, talent chain, capital chain, and innovation chain. Only through integration can we further promote industrial development. In this survey, various companies gave us good opinions and suggestions, which also helped us to further improve our suggestions. We hope to take this opportunity to collect everyone's opinions and suggestions and strive to achieve national success. The two sessions put forward targeted and systematic good suggestions to relevant departments to promote further high-quality development of the biomedical industry." Yuan Yuyu said.
Text/Guangzhou Daily all-media reporters Jia Zheng, Deng Xiaoli, Wei Lina, Zhang Shuhong